Pharma News
This Week
Nov 30, 2025
New Gelatin Hydrogel Created for Simultaneous Delivery of ARV-471 and Palbociclib in Breast Cancer Treatment
Researchers have developed a gelatin-based hydrogel for the dual delivery of ARV-471, an oral selective estrogen receptor degrader, and Palbociclib, a cyclin-dependent kinase 4/6 inhibitor, to enhance breast cancer therapy. This innovative system aims to improve drug efficacy and minimize side effects, showing promising results in preclinical models for combination treatments.
